Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Larimar TherapeuticsLRMR -5.22%34 3-1 Month Momentum % is -16.82% as of Jul. 29, 2026. GuruFocus rates LRMR with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,387 Biotechnology companies, Larimar Therapeutics ranks worse than 59.84% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-29), Larimar Therapeutics's 3-1 Month Momentum % is -16.82%.
The industry rank for Larimar Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
LRMR's 3-1 Month Momentum % is ranked worse than 59.84% of 1387
companies
in the Biotechnology industry
Industry Median: -10.62
vs LRMR: -16.82
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Larimar Therapeutics 3-1 Month Momentum % Related Terms
LRMR vs OCGN, EVMN, PBYI: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Larimar Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Larimar Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Larimar Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Larimar Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Larimar Therapeutics (LRMR) has a 3-1 Month Momentum % of -16.82% as of Jul. 29, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Larimar Therapeutics and its competitors. According to the industry distribution chart, Larimar Therapeutics ranks #830 out of 1387 companies in the Biotechnology industry, placing it in the top 59.8%.
Is Larimar Therapeutics' 3-1 Month Momentum % too high?
Larimar Therapeutics' current 3-1 Month Momentum % is -16.82%. Based on the distribution chart, Larimar Therapeutics ranks #830 out of 1387 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Larimar Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Larimar Therapeutics' 3-1 Month Momentum % compare to OCGN and EVMN?
According to the Biotechnology industry distribution chart, Larimar Therapeutics ranks #830 out of 1387 companies for 3-1 Month Momentum %. This places Larimar Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Larimar Therapeutics and its competitors. Larimar Therapeutics's current 3-1 Month Momentum % is -16.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Larimar Therapeutics stock overvalued right now?
Larimar Therapeutics (LRMR) has a current 3-1 Month Momentum % of -16.82%. The current 3-1 Month Momentum % is -16.82%. Larimar Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Larimar Therapeutics (LRMR), the current 3-1 Month Momentum % is -16.82% as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
34GF Score
Get the complete analysis for LRMR
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LRMR has been successfully added to your 
